In Quiet Debut, Alzheimer's Drug Rollout Slowed By Questions, Skepticism
Category: SCIENCE
Persistent concerns about Aduhelm, the disease's first new treatment in about 20 years, are curbing access more than four months after regulators approved it.
By Tom Murphy, AP, 2021-10-17